T细胞
CD8型
细胞毒性
癌症研究
细胞毒性T细胞
多发性骨髓瘤
兴奋剂
CD3型
抗体
药理学
生物
免疫系统
细胞生物学
化学
免疫学
受体
生物化学
体外
作者
Ji Li,Dionysos Slaga,Jennifer Johnston,Teemu T. Junttila
出处
期刊:Molecular Cancer Therapeutics
[American Association for Cancer Research]
日期:2023-02-23
标识
DOI:10.1158/1535-7163.mct-22-0498
摘要
Abstract Although CD3-bispecific antibodies have demonstrated promising activity in the treatment of hematological cancers, insufficient T cell co-stimulation may limit long-term responses. Immunomodulatory drugs (IMiDs), routinely used in treating multiple myeloma (MM), possess pleiotropic anti-myeloma properties and have been described to enhance T cell responses similar to co-stimulatory signaling and may therefore have synergistic effects when combined with T cell bispecifics. In this report, we demonstrate that IMiDs substantially enhance tumor cell killing induced by CD3-bispecifics and increase CD8+ T cell proliferation and expansion. We further show that the beneficial effects of IMiDs on T cell function and expansion are mediated by enhanced IL-2 production by CD4+ T cells. Our studies provide mechanistic insight into the co-stimulatory properties of IMiDs and support combination treatments with T cell agonist therapies in a broad spectrum of indications.
科研通智能强力驱动
Strongly Powered by AbleSci AI